Literature DB >> 29610956

Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia.

Daniele Muser1, Pasquale Santangeli1, Simon A Castro1, Jackson J Liang1, Andres Enriquez1, Thomas J Werner2, Gaetano Nucifora3, Silvia Magnani1, Tatsuya Hayashi1, Erica S Zado1, Fermin C Garcia1, David J Callans1, Sanjay Dixit1, Benoit Desjardins4, Francis E Marchlinski1, Abass Alavi5.   

Abstract

BACKGROUND: Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) has shown to be useful in diagnosis, staging and monitoring of cardiac sarcoidosis (CS) but its interpretation is not standardized.
OBJECTIVES: We sought to investigate the clinical impact of serial quantitative FDG uptake analysis in patients with CS presenting with ventricular tachycardia (VT) treated by catheter ablation (CA).
METHODS: We followed 20 patients (51 ± 9 years, 70% males) with CS and VT who underwent CA, with 92 serial FDG-PET scans (3-10 per patient). Myocardial FDG-avid lesions were quantified using three parameters: maximum standardized uptake value (SUVmax), partial-volume corrected mean standardized uptake value (SUVmean) and partial-volume corrected volume-intensity product [lesion metabolic activity (LMA)]. The volume-intensity product of the entire heart [global cardiac metabolic activity (gCMA)] and the background cardiac metabolic activity (bCMA: difference between gCMA and LMA) were also calculated. The primary end-point was the occurrence of major adverse cardiac events (MACE), including death, heart transplant, hospitalization for heart failure and implantable cardioverter defibrillator (ICD) appropriate interventions. Evolution of echocardiographic parameters over follow-up was also assessed.
RESULTS: During a median follow-up of 35 (20-66) months, 18 MACE (1 death, 2 heart transplants, 12 ICD appropriate interventions, 3 hospitalizations) occurred in 12 (60%) patients. At univariable analysis, lack of PET improvement (defined by decrease in LMA of at least 25%) was the only variable associated with cardiac events during follow-up. In particular, non-responders had a 20-fold higher risk of MACE at follow-up (HR 18.96, 95% CI 2.26-159.27; p = 0.007). Moreover, a significant linear inverse relationship was observed between changes in LMA and changes in left ventricular ejection fraction over follow-up (β = -20.11; p = 0.003).
CONCLUSIONS: In patients with CS and VT, temporal change in FDG uptake evaluated by a quantitative approach is associated with parallel change in systolic function. Moreover, reduction in FDG uptake is strongly associated with fewer MACE at long-term follow-up.

Entities:  

Keywords:  Cardiac sarcoidosis; FDG-PET; Heart failure; Metabolic activity; Ventricular tachycardia

Mesh:

Substances:

Year:  2018        PMID: 29610956     DOI: 10.1007/s00259-018-4001-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis.

Authors:  Rami Yokoyama; Masao Miyagawa; Hideki Okayama; Takeshi Inoue; Hitoshi Miki; Akiyoshi Ogimoto; Jitsuo Higaki; Teruhito Mochizuki
Journal:  Int J Cardiol       Date:  2015-05-15       Impact factor: 4.164

2.  Long-Term Outcome After Catheter Ablation of Ventricular Tachycardia in Patients With Nonischemic Dilated Cardiomyopathy.

Authors:  Daniele Muser; Pasquale Santangeli; Simon A Castro; Rajeev K Pathak; Jackson J Liang; Tatsuya Hayashi; Silvia Magnani; Fermin C Garcia; Mathew D Hutchinson; Gregory G Supple; David S Frankel; Michael P Riley; David Lin; Robert D Schaller; Sanjay Dixit; Erica S Zado; David J Callans; Francis E Marchlinski
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-10

3.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.

Authors:  David H Birnie; William H Sauer; Frank Bogun; Joshua M Cooper; Daniel A Culver; Claire S Duvernoy; Marc A Judson; Jordana Kron; Davendra Mehta; Jens Cosedis Nielsen; Amit R Patel; Tohru Ohe; Pekka Raatikainen; Kyoko Soejima
Journal:  Heart Rhythm       Date:  2014-05-09       Impact factor: 6.343

4.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis.

Authors:  Azadeh Ahmadian; Ashley Brogan; Jeffrey Berman; Aaron L Sverdlov; Gustavo Mercier; Michael Mazzini; Praveen Govender; Frederick L Ruberg; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

5.  A new technique to perform epicardial mapping in the electrophysiology laboratory.

Authors:  E Sosa; M Scanavacca; A d'Avila; F Pilleggi
Journal:  J Cardiovasc Electrophysiol       Date:  1996-06

6.  Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis.

Authors:  Shinji Ishimaru; Ichizo Tsujino; Toshiki Takei; Eriko Tsukamoto; Shinji Sakaue; Mitsunori Kamigaki; Naofumi Ito; Hiroshi Ohira; Daisuke Ikeda; Nagara Tamaki; Masaharu Nishimura
Journal:  Eur Heart J       Date:  2005-04-04       Impact factor: 29.983

7.  The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis.

Authors:  Azadeh Ahmadian; Sumeet Pawar; Praveen Govender; Jeffrey Berman; Frederick L Ruberg; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2016-07-25       Impact factor: 5.952

8.  Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy.

Authors:  Oscar Cano; Mathew Hutchinson; David Lin; Fermin Garcia; Erica Zado; Rupa Bala; Michael Riley; Joshua Cooper; Sanjay Dixit; Edward Gerstenfeld; David Callans; Francis E Marchlinski
Journal:  J Am Coll Cardiol       Date:  2009-08-25       Impact factor: 24.094

9.  Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.

Authors:  Michael T Osborne; Edward A Hulten; Avinainder Singh; Alfonso H Waller; Marcio S Bittencourt; Garrick C Stewart; Jon Hainer; Venkatesh L Murthy; Hicham Skali; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2013-12-03       Impact factor: 5.952

10.  Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial.

Authors:  Victor Y Cheng; Piotr J Slomka; Marie Ahlen; Louise E J Thomson; Alan D Waxman; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2009-12-15       Impact factor: 5.952

View more
  14 in total

1.  Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease.

Authors:  Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Thomas J Werner; Hongming Zhuang; Terence Gade; Abass Alavi; Stephen J Hunt
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

2.  A case series on inflammatory cardiomyopathy and suspected cardiac sarcoidosis: role of cardiac PET in management.

Authors:  Peter J Kennel; Farhan Raza; Jiwon Kim; Parmanand Singh; Alain Borczuk; Udhay Krishnan; Maria Karas; Irina Sobol
Journal:  Eur Heart J Case Rep       Date:  2020-08-03

3.  Controversies in the Treatment of Cardiac Sarcoidosis.

Authors:  Ogugua Ndili Obi; Elyse E Lower; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

Review 4.  Potential novel imaging targets of inflammation in cardiac sarcoidosis.

Authors:  Jakob Park; Bryan D Young; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2021-11-03       Impact factor: 3.872

5.  Incremental value of FDG-PET/CT to monitor treatment response in infectious spondylodiscitis.

Authors:  Elda Righi; Alessia Carnelutti; Daniele Muser; Fernando Di Gregorio; Barbara Cadeo; Giulia Melchioretto; Maria Merelli; Abass Alavi; Matteo Bassetti
Journal:  Skeletal Radiol       Date:  2020-01-04       Impact factor: 2.199

6.  The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis.

Authors:  R J Flores; K R Flaherty; Z Jin; S Bokhari
Journal:  J Nucl Cardiol       Date:  2018-11-12       Impact factor: 5.952

7.  Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Keunyoung Kim
Journal:  J Nucl Cardiol       Date:  2019-01-02       Impact factor: 5.952

Review 8.  Arrhythmias in Cardiac Sarcoidosis Bench to Bedside: A Case-Based Review.

Authors:  Lynda E Rosenfeld; Mina K Chung; Clifford V Harding; Paolo Spagnolo; Johan Grunewald; Jason Appelbaum; William H Sauer; Daniel A Culver; Jose A Joglar; Ben A Lin; Christine L Jellis; Timm-Michael Dickfeld; Deborah H Kwon; Edward J Miller; Paul C Cremer; Frank Bogun; Jordana Kron; Ashley Bock; Davendra Mehta; Paul Leis; Konstantinos C Siontis; Elizabeth S Kaufman; Thomas Crawford; Peter Zimetbaum; Edwin T Zishiri; Jagmeet P Singh; Kenneth A Ellenbogen; Jonathan Chrispin; Syed Quadri; Logan L Vincent; Kristen K Patton; Steven Kalbfleish; Thomas D Callahan; Francis Murgatroyd; Marc A Judson; David Birnie; David R Okada; Christopher Maulion; Pavan Bhat; Lavanya Bellumkonda; Ron Blankstein; Richard K Cheng; Maryjane A Farr; Jerry D Estep
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-02-16

9.  Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis.

Authors:  David G Rosenthal; Purvi Parwani; Tyler O Murray; Bradley J Petek; Bryan S Benn; Teresa De Marco; Edward P Gerstenfeld; Munir Janmohamed; Liviu Klein; Byron K Lee; Joshua D Moss; Melvin M Scheinman; Henry H Hsia; Van Selby; Laura L Koth; Miguel H Pampaloni; Julie Zikherman; Vasanth Vedantham
Journal:  J Am Heart Assoc       Date:  2019-09-06       Impact factor: 5.501

10.  FDG-PET in possible cardiac sarcoidosis: Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2019-02-27       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.